Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Rare & genetic · 2026

Emcitate (tiratricol)

The FDA approved Emcitate (tiratricol) on September 28, 2026 to treat peripheral thyrotoxicosis in patients with MCT8 deficiency.
Brand name
Emcitate
Generic name
tiratricol
FDA approval date
September 28, 2026
Approved use (FDA wording)
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
Category on this site
Rare & genetic

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.